ArticleBiochemical and biophysical research communications2004
Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein.
Article in Biochemical and biophysical research communications, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Preparation, Purification and Performance Evaluation of Polyclonal Antibody Against SARS-CoV-2 Produced in Rat.Advanced pharmaceutical bulletin · 2023Article
- Does infection of 2019 novel coronavirus cause acute and/or chronic sialadenitis?Medical hypotheses · 2020Article
- Cell adhesion as a novel approach to determining the cellular binding motif on the severe acute respiratory syndrome coronavirus spike protein.Journal of virological methods · 2014Article
- A DNA prime-protein boost vaccination strategy targeting turkey coronavirus spike protein fragment containing neutralizing epitope against infectious challenge.Veterinary immunology and immunopathology · 2013Article
- Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay.Journal of virological methods · 2013Article
- Severe acute respiratory syndrome and coronavirus.Infectious disease clinics of North America · 2010Review
- Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.Virologica Sinica · 2010Article
- Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2008Article
- Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.Clinical and vaccine immunology : CVI · 2007Article
- Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction.Antiviral research · 2007Article
- A study on antigenicity and receptor-binding ability of fragment 450-650 of the spike protein of SARS coronavirus.Virology · 2007Article
- False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV.Clinical and vaccine immunology : CVI · 2006Article
- Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction.Antiviral research · 2006Article
- Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization.World journal of gastroenterology · 2005Article
- A human SARS-CoV neutralizing antibody against epitope on S2 protein.Biochemical and biophysical research communications · 2005Article
- Development and evaluation of an enzyme-linked immunosorbent assay for detection of antibodies against the spike protein of SARS-coronavirus.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2005Article
- Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential.FEBS letters · 2005Article
- Prokaryotic expression, refolding, and purification of fragment 450-650 of the spike protein of SARS-coronavirus.Protein expression and purification · 2005Article
- Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.Biochemical and biophysical research communications · 2004Article
- The aetiology, origins, and diagnosis of severe acute respiratory syndrome.The Lancet. Infectious diseases · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible for binding to specific cellular receptors and is a major antigenic determinant, which induces neutralizing antibody. In order to analyze the antigenicity and receptor-binding ability of SARS-CoV S protein, we expressed the S protein in Escherichia coli using a pET expression vector. After the isopropyl-beta-D-thiogalactoside induction, S protein was expressed in the soluble form and purified by nickel-affinity chromatography to homogeneity. The amount of S protein recovered was 0.2-0.3mg/100ml bacterial culture. The S protein was recognized by sera from SARS patients by ELISA and Western blot, which indicated that recombinant S protein retained its antigenicity. By biotinylated ELISA and Western blot using biotin-labeled S protein as the probe, we identified 130-kDa and 140-kDa proteins in Vero cells that might be the cellular receptors responsible for SARS-CoV infection. Taken together, these results suggested that recombinant S protein exhibited the antigenicity and receptor-binding ability, and it could be a good candidate for further developing SARS vaccine and anti-SARS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.